Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2017 Publisher: Aventis Pharma Limited, One Onslow Street, Guildford, Surrey, GU1 4YS, UK or trading as: Sanofi-aventis or Sanofi, One Onslow Street, Guildford, Surrey, GU1 4YS, UK
Xatral XL 10 mg prolonged release tablets.
| Pharmaceutical Form |
|---|
|
Prolonged release tablet. Round biconvex, three layer tablet: one white layer between two yellow layers. |
Each tablet contains 10mg alfuzosin hydrochloride.
Excipient: Hydrogenated castor oil
For a full list of excipients, see section 6.1.
| Active Ingredient |
|---|
|
Alfuzosin is an orally active quinazoline derivative. It is a selective, peripherally acting antagonist of postsynaptic alpha-1-adrenoceptors. In vitro pharmacological studies have documented the selectivity of alfuzosin for the alpha-1-adrenoreceptors located in the prostate, bladder base and prostatic urethra. |
| List of Excipients |
|---|
|
Ethylcellulose |
Boxes with 10, 30, 50, 100 and 500 tablets in pvc/foil blister strips.
Not all pack sizes may be marketed.
Aventis Pharma Limited, One Onslow Street, Guildford, Surrey, GU1 4YS, UK
or trading as: Sanofi-aventis or Sanofi, One Onslow Street, Guildford, Surrey, GU1 4YS, UK
PL 04425/0657
02 April 2009
| Drug | Countries | |
|---|---|---|
| XATRAL | Austria, Australia, Brazil, Canada, Cyprus, Ecuador, Estonia, Finland, France, Hong Kong, Ireland, Israel, Italy, Lithuania, Malta, Mexico, Netherlands, Romania, Singapore, Tunisia, Turkey, United Kingdom, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.